Endometrial cancer begins in the inner lining of the uterus and is the most common invasive gynecologic malignancy in the United States. It is distinct from uterine sarcoma, which arises from muscle or connective tissue and has different biology and treatment. Most endometrial cancers are diagnosed after abnormal uterine bleeding leads to evaluation, and many are found while disease remains confined to the uterus. Modern management no longer relies only on older broad histologic groupings. Clinicians now integrate stage, histologic type, grade, molecular classification, lymphovascular invasion, general health, fertility goals, and patient preferences when planning care. The disease is also closely connected with metabolic and hormonal risk factors, although no individual patient should be blamed for developing cancer. Accurate discussion requires particular care with hereditary syndromes, tumor markers, fertility-sparing options, and newer immune and targeted therapies. Spirituality and emotional support may be important for some patients, but they should be guided by the patient rather than treated as substitutes for evidence-based treatment. A current overview therefore needs to combine tumor biology, early recognition, diagnosis, individualized therapy, and respectful communication (National Cancer Institute, 2026a).
Disease Biology, Hormonal Risk, and Prevention
The uterus contains an inner endometrial lining and a muscular myometrium. During the reproductive years, the endometrium responds to hormonal signals and undergoes cyclical growth and shedding. Many endometrioid cancers are associated with prolonged estrogenic stimulation that is not adequately balanced by progesterone. Obesity can increase estrogen exposure through conversion of androgens in adipose tissue, while chronic anovulation can reduce regular progesterone exposure. Other established risk factors include older age, endometrial hyperplasia, early menarche, late menopause, never having given birth, polycystic ovary syndrome, diabetes, unopposed postmenopausal estrogen therapy, tamoxifen use, and certain hereditary conditions. These factors increase probability rather than determine outcome. Most people with one or more risk factors do not develop endometrial cancer, and risk counseling should support prevention and early evaluation rather than encourage blame or stigma (National Cancer Institute, 2026b).
Several factors are associated with reduced risk, including combined oral contraceptive use, pregnancy, breastfeeding, and some forms of progestin exposure. Weight management and physical activity may also reduce risk through metabolic and hormonal pathways, but no lifestyle strategy guarantees prevention. People with very high hereditary risk may discuss risk-reducing surgery after childbearing with specialists. Routine screening of average-risk asymptomatic people has not been shown to reduce mortality, which is why symptom recognition remains so important. The most clinically significant warning sign is abnormal uterine bleeding, especially any bleeding after menopause. Prompt evaluation matters because early-stage endometrial cancer is often highly treatable. The disease should therefore be approached through realistic risk reduction and timely diagnosis rather than through the idea that individuals can completely control whether cancer develops (National Cancer Institute, 2026b).
Histology, Molecular Classification, and Hereditary Risk
Endometrioid adenocarcinoma is the most common histologic type, but serous carcinoma, clear-cell carcinoma, carcinosarcoma, undifferentiated carcinoma, and other uncommon forms may behave differently. Histology and grade remain important because they influence recurrence risk and treatment decisions, yet they are now interpreted alongside molecular changes. Contemporary classification commonly separates tumors into POLE-ultramutated, mismatch-repair-deficient, no-specific-molecular-profile, and p53-abnormal groups. These categories provide prognostic information that can modify the interpretation of microscopic appearance. Some POLE-mutated tumors have excellent outcomes despite alarming histologic features, while p53-abnormal tumors often behave more aggressively. Molecular classification does not replace pathology, staging, or clinical judgment; it adds another layer of information that helps the cancer team estimate risk and select therapy more precisely (National Cancer Institute, 2026a).
Hereditary syndromes are important because endometrial cancer can be the first cancer that leads to recognition of an inherited risk in a family. Lynch syndrome results from pathogenic variants affecting DNA mismatch-repair genes and increases the risk of endometrial, colorectal, and several other cancers. Tumor testing for mismatch-repair deficiency or microsatellite instability can identify patients who may benefit from genetic evaluation and can also guide treatment in advanced disease. A positive tumor screen does not automatically prove that a person has an inherited mutation; germline testing and genetic counseling are needed to clarify inherited risk. Cowden syndrome, associated with pathogenic variants in PTEN, is another recognized hereditary condition. Most endometrial cancers are not explained by a known inherited syndrome, so statements that assign one fixed percentage to hereditary disease should be used cautiously. Family history and tumor characteristics should guide further assessment (National Cancer Institute, 2026c).
Symptoms, Diagnostic Evaluation, and Staging
Abnormal uterine bleeding is the central warning sign. Any postmenopausal bleeding requires timely evaluation even though many cases are caused by benign conditions. In premenopausal patients, bleeding between periods, unusually heavy or prolonged bleeding, or a persistent change from the person’s normal pattern may justify investigation. Pelvic pressure, pain, unusual discharge, or unexplained weight loss can occur but are less specific. Evaluation begins with history, medication and hormone review, family history, examination, and assessment of pregnancy possibility where relevant. Transvaginal ultrasound can measure endometrial thickness and identify structural abnormalities, especially in postmenopausal bleeding, but imaging alone does not diagnose cancer. Definitive diagnosis requires endometrial tissue obtained through office biopsy, hysteroscopy with directed sampling, dilation and curettage, or another appropriate method. Persistent symptoms still require attention when an initial sample is inadequate or negative, because focal lesions can occasionally be missed (National Cancer Institute, 2026a, 2026b).
Pathology establishes the tumor type and grade and may assess molecular markers, while imaging and surgery help determine the extent of disease. FIGO staging describes involvement of the uterus, cervix, lymph nodes, adnexa, peritoneum, and distant organs, with contemporary staging increasingly integrating histologic and molecular information. Stage and grade should not be confused: stage describes how far the cancer has spread, while grade describes microscopic features associated with aggressiveness. Many patients are diagnosed early because bleeding prompts evaluation, which is one reason outcomes are often favorable for low-risk disease confined to the uterus. Prognosis becomes less favorable with aggressive histology, deep invasion, nodal involvement, or distant spread. Population survival statistics describe groups rather than predicting the outcome of one individual and should be communicated with appropriate uncertainty (FIGO Committee on Women’s Cancer, 2023; National Cancer Institute, 2026a).
Surgery, Radiation, and Systemic Treatment
Surgery is the main treatment for many patients with disease that can be removed. Total hysterectomy with removal of both fallopian tubes and ovaries is common, and minimally invasive techniques are frequently possible. Sentinel lymph-node mapping or additional nodal assessment may be used according to risk. Surgical planning should consider age, comorbidities, histology, prior procedures, molecular features, and whether there is evidence of extrauterine disease. Selected younger patients with low-grade endometrioid cancer apparently confined to the endometrium may consider fertility-sparing treatment with progestin therapy instead of immediate hysterectomy. This approach requires expert pathology review, imaging, informed consent, and frequent endometrial reassessment because response is not guaranteed and recurrence can occur. Hysterectomy is generally recommended after childbearing or when conservative treatment fails (National Cancer Institute, 2026a).
Adjuvant treatment depends on recurrence risk rather than being required for every patient. Vaginal brachytherapy can reduce local recurrence while limiting exposure to surrounding organs, whereas external-beam radiation treats a wider pelvic area. Chemotherapy is used in many high-risk, advanced, or recurrent cancers, with carboplatin and paclitaxel among the commonly used agents. Hormonal treatment can be useful for selected low-grade or hormone-receptor-positive disease. Immune checkpoint inhibitors and other targeted or biological therapies have expanded options in advanced and recurrent cancer, particularly when mismatch-repair deficiency, microsatellite instability, or other relevant molecular features are present. These treatments can produce important benefit but may also cause significant toxicity and therefore require specialist monitoring. Therapy should be chosen for the individual tumor and patient rather than according to a single universal sequence (National Cancer Institute, 2026a).
Survivorship, Communication, and Patient-Centered Care
Care does not end when active treatment is completed. Follow-up focuses on symptoms, examination, treatment effects, health maintenance, and individualized risk rather than automatic intensive imaging for every survivor. Patients may need support for lymphedema, surgical menopause, sexual health, fertility loss, neuropathy, fatigue, bone health, mental health, cardiovascular risk, and fear of recurrence. Racial disparities in U.S. outcomes, including poorer outcomes reported among Black women, cannot be explained by one factor. Differences in stage, tumor biology, access to gynecologic oncology, comorbidities, treatment patterns, and structural inequities can all contribute. Survivorship care should therefore address not only surveillance for recurrence but also long-term physical and social consequences of diagnosis and treatment (National Cancer Institute, 2026a).
Communication is an essential component of treatment. A diagnosis should be discussed privately, clearly, and at a pace the patient can absorb. Clinicians should explain what is known, what remains uncertain, which decisions are urgent, and what options are available. Fertility, sexual function, menopause, and hereditary implications should be raised proactively because patients may find these topics difficult to initiate. Spirituality can also be important for some individuals as a source of meaning, community, hope, fear, or conflict. Clinicians can ask whether spiritual concerns matter to the patient and offer chaplaincy or community support when desired. They should not assume that religious faith opposes scientific medicine, impose beliefs, or suggest that illness reflects punishment. Patient-centered care respects both evidence and the individual’s values while maintaining informed consent and autonomy (Puchalski, 2001).
Conclusion
Endometrial cancer is a diverse group of malignancies arising from the uterine lining, most often brought to medical attention by abnormal bleeding. Modern diagnosis and treatment require more than the older division of tumors into a few broad histologic types. Stage, grade, histology, molecular classification, hereditary risk, general health, and fertility goals all influence management. Obesity, prolonged unopposed estrogenic exposure, chronic anovulation, age, metabolic disease, tamoxifen, and hereditary syndromes can increase risk, but none should be used to blame the patient. Tissue sampling is necessary for diagnosis, surgery cures many early cases, and radiation, chemotherapy, hormonal therapy, immunotherapy, and targeted treatment have defined roles according to disease risk and molecular characteristics. The most important practical opportunity remains early evaluation of abnormal uterine bleeding, particularly after menopause. High-quality care also requires attention to survivorship, fertility, sexuality, family risk, emotional health, and spirituality so that treatment remains scientifically accurate without losing sight of the person experiencing the disease (National Cancer Institute, 2026a, 2026b, 2026c).
References
National Cancer Institute. (2026a). Endometrial Cancer Treatment (PDQ®).
National Cancer Institute. (2026b). Endometrial Cancer Prevention and Screening (PDQ®).
National Cancer Institute. (2026c). Genetics of Breast and Gynecologic Cancers (PDQ®).
FIGO Committee on Women’s Cancer. (2023). FIGO staging of endometrial cancer.
Puchalski, C. M. (2001). The role of spirituality in health care. Proceedings (Baylor University Medical Center), 14(4), 352–357.
Academic Master Education Team is a group of academic editors and subject specialists responsible for producing structured, research-backed essays across multiple disciplines. Each article is developed following Academic Master’s Editorial Policy and supported by credible academic references. The team ensures clarity, citation accuracy, and adherence to ethical academic writing standards
Content reviewed under Academic Master Editorial Policy.
